Financial Headwinds Mount for Milestone and Mirum Pharmaceuticals as Both Burn Through Cash
核心洞察
Milestone Pharmaceuticals reported an operating loss of $62 million over the last twelve months with an operating margin of -4019%, signaling severe profitability challenges.
Mirum Pharmaceuticals posted a $70 million operating loss (LTM) despite a 130% stock price surge over the past 12 months, raising valuation concerns.
Both companies remain cash-flow negative, with Milestone's free cash flow margin at -3192% and Mirum's at -32%, underscoring unsustainable burn rates.
Milestone Pharmaceuticals and Mirum Pharmaceuticals, two clinical-stage biopharmaceutical companies, are facing intensifying financial scrutiny as both firms report deep operating losses and negative cash flows, according to financial data from Trefis. The figures paint a picture of companies heavily reliant on external financing to sustain operations while delivering minimal revenue.
Milestone Pharmaceuticals: Operating at a Severe Deficit
Milestone Pharmaceuticals (MIST) recorded an operating loss of $62 million over the last twelve months (LTM), with its operating margin plunging to -4019%. This metric reflects the company's profitability before taxes and before the impact of capital structure, including interest payments.
The company's price-to-sales (P/S) ratio stands at 88x, indicating an expensive valuation relative to its current revenue generation. Share-based compensation (SBC) has reached 483% of revenue over the LTM period, a level that raises significant concerns about shareholder dilution.
Cash flow metrics further underscore the financial strain. Milestone's cash flow from operations relative to revenue (CFO/Rev LTM) sits at -3172%, while free cash flow margin (FCF/Rev LTM) is -3192%. The company's equity risk premium (ERP), calculated as total yield minus the risk-free rate, is -51%, suggesting investors are not being compensated for the risk assumed.
Mirum Pharmaceuticals: Stock Rally Masks Underlying Losses
Mirum Pharmaceuticals (MIRM) presents a contrasting picture in market performance versus financial fundamentals. While the company's stock price has surged 130% over the past 12 months, its operating income remains deeply negative at -$70 million (LTM), with an operating margin of -12%.
The stock's recent run-up has driven valuation multiples higher, with the P/S ratio increasing by 62% over the past six months. Share-based compensation accounts for 16% of revenue, a more moderate but still notable figure.
Mirum's cash flow position, while less dire than Milestone's, remains negative. Cash flow from operations is -30% of revenue, and free cash flow is -32% of revenue. The company's ERP stands at -15%, also indicating a negative yield relative to risk-free assets.
Comparative Financial Health
Neither company is profitable at the operating income level, and both remain non-cash-flow generative. The magnitude of Milestone's negative margins far exceeds those of Mirum, though Mirum's rapidly appreciating stock price has made its valuation increasingly expensive on a P/S basis. For investors, the key question is whether either company can transition toward sustainable operations before requiring additional capital infusions.